UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
|
|
|||
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification Number) |
(Address of principal executive offices, including Zip Code)
Registrant’s telephone number, including area code:
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered or to be registered pursuant to Section 12(b) of the Act.
Title of each class |
|
Trading Symbol |
|
Name of each exchange on which registered |
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02 Results of Operations and Financial Condition.
On May 10, 2022, IDEAYA Biosciences, Inc. (the “Company”) announced its financial results for the first quarter ended March 31, 2022. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Item 2.02 and the attached Exhibit 99.1 are being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall they be deemed to be incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. |
|
Description |
|
|
|
99.1 |
|
|
|
|
|
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
IDEAYA BIOSCIENCES, INC. |
|
|
|
Date: May 10, 2022 |
By: |
/s/ Yujiro Hata |
|
|
Yujiro Hata |
|
|
President and Chief Executive Officer |
Exhibit 99.1
IDEAYA Biosciences, Inc. Reports First Quarter 2022
Financial Results and Provides Business Update
South San Francisco, CA, May 10, 2022– IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, provided a business update and announced financial results for the first quarter ended March 31, 2022.
"The IDE397 Phase 1 dose escalation clinical data supports advancing the program to monotherapy expansions and clinical combinations in patients with MTAP deletion tumors. In addition, the darovasertib Phase 2 data is maturing to enable FDA discussions on potential registrational trial design in MUM, and we are preclinically exploring potential darovasertib expansion opportunities in additional cMET driven tumors,” said Yujiro S. Hata, Chief Executive Officer and President of IDEAYA Biosciences.
“We are building a broad and deep pipeline of potential first-in-class synthetic lethality therapeutics. Several of our synthetic lethality programs are advancing toward the clinic, including our PARG inhibitor, IDE161, for which we are targeting an IND in Q4 2022, and our potential first-in-class Pol Theta helicase inhibitor, for which we are collaborating with GSK to select a development candidate in Q2 2022. Our potential first in class Werner helicase inhibitor is also progressing in collaboration with GSK; we are targeting development candidate selection in 2023,” said Michael White, Senior Vice President and Chief Scientific Officer of IDEAYA Biosciences.
Program Updates
Key highlights for IDEAYA’s pipeline programs include:
IDE397 (MAT2A)
IDEAYA is evaluating IDE397, a potent and selective small molecule inhibitor targeting methionine adenosyltransferase 2a (MAT2A), in patients having solid tumors with methylthioadenosine phosphorylase (MTAP) deletion, a patient population estimated to
represent approximately 15% of solid tumors. IDEAYA is leading early clinical development of IDE397. Subject to exercise of its option for an exclusive license, GlaxoSmithKline (GSK) will lead global clinical development. Highlights:
PARG
IDEAYA is advancing preclinical research for an inhibitor of poly (ADP-ribose) glycohydrolase (PARG) in patients having tumors with a defined biomarker based on genetic mutations and/or molecular signature. PARG is a novel target in the same clinically validated biological pathway as poly (ADP-ribose) polymerase (PARP). IDEAYA owns or controls all commercial rights in its PARG program. Highlights:
Pol Theta
IDEAYA’s DNA Polymerase Theta, (Pol Theta) program targets tumors with BRCA or other homologous recombination (HR) mutations or homologous recombination deficiency (HRD). IDEAYA and GSK are collaborating on ongoing preclinical research, including small molecules and protein degraders, and GSK will lead clinical development for the Pol Theta program. Highlights:
Werner Helicase
IDEAYA is advancing preclinical research for an inhibitor targeting Werner Helicase for tumors with high microsatellite instability (MSI). IDEAYA and GSK are collaborating on ongoing preclinical research, and GSK will lead clinical development for the Werner Helicase program. Highlights:
Other Synthetic Lethality Pipeline Programs
IDEAYA is advancing additional preclinical research programs to identify small molecule inhibitors for an MTAP-synthetic lethality target, as well as for multiple potential first-in-class synthetic lethality programs for patients with solid tumors characterized by proprietary biomarkers or gene signatures.
Darovasertib (IDE196)
IDEAYA continues to execute on its clinical trial strategy to evaluate darovasertib (IDE196), a potent and selective PKC inhibitor.
IDEAYA is evaluating darovasertib in combination with crizotinib, a cMET inhibitor, in metastatic uveal melanoma (MUM). The company is also clinically evaluating darovasertib as a combination with crizotinib in GNAQ/11 mutant skin melanoma in an ongoing arm of the current clinical trial, and in adjuvant primary uveal melanoma (UM) as monotherapy through an investigator sponsor clinical trial (IST). IDEAYA is also evaluating other potential darovasertib expansion opportunities, including in cMET driven tumors and in KRAS-mutation tumors.
Darovasertib / Crizotinib Combination Therapy
IDEAYA is continuing patient enrollment into the darovasertib / crizotinib combination arm of the Phase 1/2 clinical trial under clinical trial collaboration and supply agreements with Pfizer. Highlights:
Darovasertib Monotherapy
IDEAYA has completed enrollment into its ongoing Phase 1/2 clinical trial evaluating darovasertib as monotherapy in MUM patients.
IDEAYA is planning to initiate an Investigator Sponsored Trial, with St. Vincent’s Hospital Sydney Limited to evaluate darovasertib as monotherapy in a neo-adjuvant / adjuvant setting in (non-metastatic) uveal melanoma (UM) patients.
Darovasertib – Other Potential Indications
IDEAYA is evaluating the potential for darovasertib in other oncology indications, including in cMET-driven tumors and in KRAS-mutation tumors. Highlights:
General
IDEAYA continues to monitor Covid-19 and its potential impact on clinical trials and timing of clinical data results. Initiation of clinical trial sites, patient enrollment and ongoing monitoring of enrolled patients, including obtaining patient computed tomography (CT) scans, may be impacted for IDEAYA clinical trials evaluating IDE397 and darovasertib; the specific impacts are currently uncertain.
Corporate Updates
IDEAYA’s net losses were $14.0 million and $18.2 million for the three months ended March 31, 2022 and December 31, 2021, respectively. As of March 31, 2022, the company had an accumulated deficit of $190.8 million.
As of March 31, 2022, IDEAYA had cash, cash equivalents and marketable securities of $346.2million. IDEAYA believes that its cash, cash equivalents and marketable securities will be sufficient to fund its planned operations into 2025. These funds will support the company’s efforts through potential achievement of multiple preclinical and clinical milestones across multiple programs.
Our updated corporate presentation is available on our website, at our Investor Relations page: https://ir.ideayabio.com/.
Financial Results
As of March 31, 2022, IDEAYA had cash, cash equivalents and short-term marketable securities totaling $346.2 million. This compared to cash, cash equivalents and short-term and long-term marketable securities of $368.1 million at December 31, 2021. The decrease was primarily due to cash used in operations.
Collaboration revenue for the three months ended March 31, 2022 totaled $11.4 million compared to $3.0 million for the three months ended December 31, 2021. Collaboration revenue was recognized for the performance obligations satisfied through March 31, 2022 under the GSK Collaboration Agreement.
Research and development (R&D) expenses for the three months ended March 31, 2022 totaled $19.7 million compared to $16.1 million for the three months ended December 31, 2021. The increase was primarily due to higher personnel-related expenses, clinical trial expenses and consulting fees.
General and administrative (G&A) expenses for the three months ended March 31, 2022 totaled $5.9 million compared to $5.2 million for the three months ended December 31, 2021. The increase was primarily due to higher personnel-related expenses and consulting fees.
The net loss for the three months ended March 31, 2022 was $14.0 million compared to $18.2 million for the three months ended December 31, 2021. Total stock compensation expense for
the three months ended March 31, 2022 was $2.6 million compared to $2.1 million for the three months ended December 31, 2021.
About IDEAYA Biosciences
IDEAYA is a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA’s approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets.
Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to (i) the extent to which IDEAYA’s existing cash, cash equivalents, and marketable securities will fund its planned operations, (ii) the timing of monotherapy cohort expansion and combination cohort initiation in the IDE397 Phase 1 clinical trial, (iii) the timing of the delivery of the GSK option data package, (iii) the timing and content of an additional clinical data update for the darovasertib and crizotinib combination, (iv) the timing of submitting an IND for PARG inhibitor, IDE161, (v) the timing of identification of a development candidate and initiating IND-enabling studies for a Pol Theta inhibitor, (vi) the timing of identification of a development candidate for a Werner Helicase inhibitor, (vii) the potential receipt of GSK milestone payments, (viii) the timing of obtaining FDA guidance for potential registration-enabling trial design to evaluate the darovasertib and crizotinib combination, (ix) the initiation of an IST to evaluate ID196 in a neo-adjuvant / adjuvant setting, (xi) and (x) the impact of COVID-19. Such forward-looking statements involve substantial risks and uncertainties that could cause IDEAYA’s preclinical and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including IDEAYA’s programs’ early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, IDEAYA’s ability to successfully establish, protect and defend its intellectual property, the effects on IDEAYA’s business of the worldwide COVID-19 pandemic, the ongoing military conflict between Russia and Ukraine, and other matters that could affect the sufficiency of existing cash to fund operations. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA’s recent Quarterly Report on Form 10-Q filed on May 10, 2022 and any current and periodic reports filed with the U.S. Securities and Exchange Commission.
Investor and Media Contact
IDEAYA Biosciences
Paul Stone
Senior Vice President and Chief Financial Officer
investor@ideayabio.com
IDEAYA Biosciences, Inc.
Condensed Statements of Operations and Comprehensive Loss
(in thousands, except share and per share amounts)
(Unaudited)
|
|
Three Months Ended |
|
|||||
|
|
March 31, 2022 |
|
|
December 31, 2021 |
|
||
Collaboration revenue |
|
$ |
11,359 |
|
|
$ |
2,963 |
|
Operating expenses: |
|
|
|
|
|
|
||
Research and development |
|
|
19,656 |
|
|
|
16,109 |
|
General and administrative |
|
|
5,923 |
|
|
|
5,223 |
|
Total operating expenses |
|
|
25,579 |
|
|
|
21,332 |
|
Loss from operations |
|
|
(14,220 |
) |
|
|
(18,369 |
) |
Interest income and other income, net |
|
|
207 |
|
|
|
157 |
|
Net loss |
|
|
(14,013 |
) |
|
|
(18,212 |
) |
Unrealized loss on marketable securities |
|
|
(2,092 |
) |
|
|
(662 |
) |
Comprehensive loss |
|
$ |
(16,105 |
) |
|
$ |
(18,874 |
) |
Net loss per share attributable to common |
|
$ |
(0.36 |
) |
|
$ |
(0.47 |
) |
Weighted-average number of shares outstanding, |
|
|
38,591,966 |
|
|
|
38,501,335 |
|
IDEAYA Biosciences, Inc.
Condensed Balance Sheet Data
(in thousands)
|
|
March 31, 2022 |
|
|
December 31, 2021 |
|
||
|
|
(Unaudited) |
|
|
|
|
||
Cash and cash equivalents and short-term and long-term |
|
$ |
346,227 |
|
|
$ |
368,063 |
|
Total assets |
|
|
358,867 |
|
|
|
381,347 |
|
Total liabilities |
|
|
70,200 |
|
|
|
79,833 |
|
Total liabilities and stockholders' equity |
|
|
358,867 |
|
|
|
381,347 |
|
Document And Entity Information |
May 10, 2022 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | May 10, 2022 |
Entity Registrant Name | IDEAYA Biosciences, Inc. |
Entity Central Index Key | 0001676725 |
Entity Emerging Growth Company | true |
Entity File Number | 001-38915 |
Entity Incorporation, State or Country Code | DE |
Entity Tax Identification Number | 47-4268251 |
Entity Address, Address Line One | 7000 Shoreline Court |
Entity Address, Address Line Two | Suite 350 |
Entity Address, City or Town | South San Francisco |
Entity Address, State or Province | CA |
Entity Address, Postal Zip Code | 94080 |
City Area Code | (650) |
Local Phone Number | 443-6209 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Entity Ex Transition Period | true |
Title of 12(b) Security | Common Stock, $0.0001 par value per share |
Trading Symbol | IDYA |
Security Exchange Name | NASDAQ |
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end
*\^
M*FHBQ8:S,=2Y!OQM5;%5Q6]3%8_K/,5F9A3->@$8Y= %>')MN;^25$#KD-YJ
M,;<>.MD3$BN&?W% J(]=GSDXHH&'H\!S'>XY<1 ]>>&P=N5FEAT;LVF3A%FO
M>(+H#LN=I%_TMT'*"%P*=!YS2="C31EQ:/7C;]YT;F67@ET\HW"1IAS+E'
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M"PE-:^#(H-OPBQ+GLH#W8$K1"7W ?J*,Z _/T?./T1"-XSFD!/5%
MG*? -<)HKG76"8+%8N$G4\J58+DV<,J/11H@C*O@MQ*(E:,^T8 ZC;#1P&$+
MA^W'1J-C/JVFW[R\O/@6AITPK+F);"7I;*[167R.K)?!YAP86Z$[R@F/*6%H
M[$"_HP&/?73#&!I9+X5&H$"^0>*7,9 9R;AHWD:%V6N@:);A]/]7;,Z.6D;_]'H
MD3T\C08GW 2!)DO!1;HJR8W,OQ=WA[OO&Y[\Y(;7:F#&2:8%)P]1 6T2 7^#PB$0"#